Literature DB >> 20102918

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance.

Steven C Halbert1, Benjamin French, Ram Y Gordon, John T Farrar, Kathryn Schmitz, Patti B Morris, Paul D Thompson, Daniel J Rader, David J Becker.   

Abstract

Currently, no consensus has been reached regarding the management of hyperlipidemia in patients who develop statin-associated myalgia (SAM). Many statin-intolerant patients use alternative lipid-lowering therapies, including red yeast rice. The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia. The study was conducted in a community-based setting in Philadelphia, Pennsylvania. A total of 43 adults with dyslipidemia and a history of statin discontinuation because of myalgia were randomly assigned to red yeast rice 2,400 mg twice daily or pravastatin 20 mg twice daily for 12 weeks. All subjects were concomitantly enrolled in a 12-week therapeutic lifestyle change program. The primary outcomes included the incidence of treatment discontinuation because of myalgia and a daily pain severity score. The secondary outcomes were muscle strength and plasma lipids. The incidence of withdrawal from medication owing to myalgia was 5% (1 of 21) in the red yeast rice group and 9% (2 of 22) in the pravastatin group (p = 0.99). The mean pain severity did not differ significantly between the 2 groups. No difference was found in muscle strength between the 2 groups at week 4 (p = 0.61), week 8 (p = 0.81), or week 12 (p = 0.82). The low-density lipoprotein cholesterol level decreased 30% in the red yeast rice group and 27% in the pravastatin group. In conclusion, red yeast rice was tolerated as well as pravastatin and achieved a comparable reduction of low-density lipoprotein cholesterol in a population previously intolerant to statins. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20102918     DOI: 10.1016/j.amjcard.2009.08.672

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  29 in total

Review 1.  Drug-related myopathies of which the clinician should be aware.

Authors:  Ritu Valiyil; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

Review 2.  The role of red yeast rice for the physician.

Authors:  Ram Y Gordon; David J Becker
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

Review 3.  Red yeast rice for the treatment of dyslipidemia.

Authors:  Frances M Burke
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 4.  Red yeast rice for dysipidemia.

Authors:  Shariq Shamim; Firas J Al Badarin; James J DiNicolantonio; Carl J Lavie; James H O'Keefe
Journal:  Mo Med       Date:  2013 Jul-Aug

Review 5.  Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?

Authors:  Marc-Andre Cornier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

6.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.

Authors:  Gabriela Mazzanti; Paola Angela Moro; Emanuel Raschi; Roberto Da Cas; Francesca Menniti-Ippolito
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

Review 7.  Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Authors:  Natalie C Ward; Jing Pang; Jacqueline D M Ryan; Gerald F Watts
Journal:  Clin Cardiol       Date:  2018-01-24       Impact factor: 2.882

Review 8.  A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes.

Authors:  Jonathan P Nieves; Seth J Baum
Journal:  Cardiovasc Endocrinol       Date:  2017-02-15

Review 9.  Statin intolerance: diagnosis and remedies.

Authors:  Angela Pirillo; Alberico Luigi Catapano
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

10.  Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.

Authors:  Yan-jun Jia; Yan Zhang; Jun Liu; Yuan-lin Guo; Rui-xia Xu; Jian-jun Li
Journal:  Chin J Integr Med       Date:  2014-07-04       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.